Transforming precision oncology into a scalable, sustainable business model that improves patient outcomes while reducing healthcare costs.
Head-and-neck cancer patients, affecting 1.4 million patients globally each year and comprising 7.6% of all cancers with the lowest immunotherapy response rates.
Clinical institutions: academic medical centers, comprehensive cancer centers, and regional hospitals that administer immunotherapy.
Oncologists and pathologists who make treatment decisions, seeking to validate tumor board decisions and reduce treatment uncertainty.
OncoMap's clinician customers value resources that reduce uncertainty around immunotherapy response, validate treatment selection, and decrease the likelihood of incorrect decisions to reduce unwarranted treatment costs.
Institutional buyers prioritize cost containment, efficacy improvement, and operational efficiency. With PD-1 immunotherapy costing over $150,000 per patient, modest accuracy improvements translate into significant savings.
OncoMap fits into the broader ecosystem as a software-based clinical decision support layer that complements existing diagnostics rather than replacing them, maximizing accuracy and precision.
Fred Hutchinson Cancer Center (Bellevue, Washington) serves as our initial traction point. OncoMap's team has direct support from Dr. Holland and interns at this leading cancer center.
This enables rapid internal validation, clinician feedback, and development of trust and credibility within the industry.
UW Medicine expansion leveraging close clinical and research ties with Fred Hutch to introduce OncoMap as a low-risk pilot tool for head-and-neck cancer care.
Attraction reinforced through validation studies, clinician-facing demonstrations, and case studies showing improved immunotherapy decision-making.
Direct institutional licensing targeting cancer center departments rather than individual oncologists. Strategic partnerships with academic medical centers, sequencing providers, and oncology networks to scale adoption efficiently.
OncoMap generates revenue through institutional subscriptions with token-based patient analysis credits, creating predictable recurring revenue that scales with patient volume.
Higher-value product for PD-1 treatment decisions
$1,000/year
Base subscription includes 50 tokens
$5 per token
Additional patient analyses
Value: Directly informs treatment decisions, helping save $150,000 per patient on ineffective immunotherapy
Routine treatment planning and research
$500/year
Base subscription includes 50 tokens
$3 per token
Additional patient analyses
Value: Supports broader use in routine treatment planning and research applications
Initial Startup Costs
$10,000
Cloud, deployment, datasets
Annual Operating Costs
$2-3K
Hosting, compute, maintenance
Per-Patient Cost
$0.05-0.10
Minimal delivery costs
Combined annual revenue per institution: ~$1,000-$1,200
Break-even point: 5-10 institutions
Timeline: Achievable within first year
$10-15K
Initial funding for one-year development and pilot deployment
Cloud-based CPU compute for RNA-seq processing, model training/testing, and secure data storage. Costs may decrease with efficient penalized regressions and k-nearest-neighbors models.
Public bulk-RNA-seq datasets with limited licensing costs. Minimized through academic access with Fred Hutch Cancer Center and other partners.
Interface refinement, backend APIs, and hosting costs to create a production-ready clinical platform.
Clinical demonstrations, validation studies, and relationship building with institutional partners.
Intellectual property consultations and licensing requirements to protect OncoMap's proprietary algorithms and ensure compliance.
Interested in bringing OncoMap to your institution or learning more about partnership opportunities?